Elicio Therapeutics (ELTX) Total Non-Current Liabilities (2021 - 2026)

Elicio Therapeutics (ELTX) has 6 years of Total Non-Current Liabilities data on file, last reported at $20.5 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 26.1% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.5 million (up 26.1% YoY) and the FY2025 annual result came in at $21.6 million, down 41.05% from the prior year.
• Total Non-Current Liabilities declined to $20.5 million in Q1 2026, from $21.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $36.7 million in Q4 2024 to a low of $11.0 million in Q2 2022.
• A 5-year average of $20.2 million and a median of $18.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 132.6% — and 2025, when it plunged 41.05%.
• Tracing ELTX's Total Non-Current Liabilities over 5 years: stood at $11.0 million in 2022, then surged by 43.66% to $15.8 million in 2023, then soared by 132.6% to $36.7 million in 2024, then sank by 41.05% to $21.6 million in 2025, then fell by 5.02% to $20.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $20.5 million (Q1 2026), $21.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.